Skip to main content

Camp4 Therapeutics Corp

For the period ended Dec 31, 2024. Filed Mar 27, 2025.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Mar 27, 2025

CAMP$4.33-7.7%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Power of Attorney (included on signature page)

POWER OF ATTORNEY

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Josh Mandel-Brehm and Kelly Gold, and each of them, as his or her true and lawful agents, proxies and attorneys-in-fact, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities to sign this Annual Report on Form 10-K of CAMP4 Therapeutics Corporation, and any or all amendments thereto, and to file the same, with all exhibits thereto, and all other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents full power and authority to do and perform each and every act and thing requisite or necessary to be done in and about the premises hereby ratifying and confirming all that such agent, proxy and attorney-in-fact or any of his substitutes, may lawfully do or cause to be done by virtue thereof.

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

SignatureTitleDate
/s/ Josh Mandel-BrehmPresident, Chief Executive Officer and Director (Principal Executive Officer)March 27, 2025
Josh Mandel-Brehm
/s/ Kelly GoldChief Financial Officer (Principal Financial Officer and Principal Accounting Officer)March 27, 2025
Kelly Gold
/s/ Steven HoltzmanDirector and ChairMarch 27, 2025
Steven Holtzman
/s/ James BoylanDirectorMarch 27, 2025
James Boylan
/s/ Ingo ChakravartyDirectorMarch 27, 2025
Ingo Chakravarty
/s/ Michael HigginsDirectorMarch 27, 2025
Michael Higgins
/s/ Amir NashatDirectorMarch 27, 2025
Amir Nashat, ScD
/s/ Paula RaganDirectorMarch 27, 2025
Paula Ragan, PhD
/s/ Andrew SchwabDirectorMarch 27, 2025
Andrew Schwab
/s/ Murray StewartDirectorMarch 27, 2025
Murray Stewart, DM FRCP
/s/ Ravi ThadhaniDirectorMarch 27, 2025
Ravi Thadhani, MD, MPH
/s/ Douglas WilliamsDirectorMarch 27, 2025
Douglas Williams, PhD
/s/ Richard YoungDirectorMarch 27, 2025
Richard Young, PhD
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.